Literature DB >> 10411671

Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers.

C González1, T Martín, J Cacho, M T Breñas, T Arroyo, B García-Berrocal, J A Navajo, J M González-Buitrago.   

Abstract

BACKGROUND: Copper (Cu) and zinc (Zn) have been implicated in the development of Alzheimer's disease (AD) and, in this regard, Cu and Zn serum concentrations have been analysed but with inconclusive results. Serum insulin, glucose and cholesterol concentrations have been related to the apolipoprotein E genotype in non-AD populations.
DESIGN: In this study, we have analysed the relationship between serum Cu, Zn, insulin, glucose and lipid parameters (cholesterol, triglycerides, apoA and apoB apolipoproteins) in AD and AD epsilon 4 apolipoprotein E carriers by multivariate analysis using logistic regression, including the variables that showed a significance of P < 0.05 in the bivariate analysis.
RESULTS: The results obtained show that epsilon 4 apoE allele is an independent AD risk factor (OR = 6. 67, 95% CI = 2.59-17.16). In AD epsilon 4 apoE allele carriers, we found significantly higher Zn, Cu and insulin serum concentrations. Non-demented control subjects with at least one epsilon 4 apoE allele had the lowest serum insulin concentrations. There was no significant association between epsilon 4 apolipoprotein E allele and lipid parameters in the sample studied.
CONCLUSIONS: In AD we have found a significant association between higher serum Zn, Cu and insulin concentrations and the presence of an epsilon 4 apoE allele, but only greater serum Zn concentration appears to be an independent risk factor associated with the development of AD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411671     DOI: 10.1046/j.1365-2362.1999.00471.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  24 in total

1.  Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.

Authors:  H Kessler; F-G Pajonk; P Meisser; T Schneider-Axmann; K-H Hoffmann; T Supprian; W Herrmann; R Obeid; G Multhaup; P Falkai; T A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 2.  A potential role for zinc alterations in the pathogenesis of Alzheimer's disease.

Authors:  Ganna Lyubartseva; Mark A Lovell
Journal:  Biofactors       Date:  2012-03-23       Impact factor: 6.113

3.  Serum zinc in the progression of Alzheimer's disease.

Authors:  Jiang Dong; J David Robertson; William R Markesbery; Mark A Lovell
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 4.  A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease.

Authors:  Mark A Lovell
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

5.  Plasma trace elements and cognitive function in older men and women: the Rancho Bernardo study.

Authors:  P K Lam; D Kritz-Silverstein; E Barrett Connor; D Milne; F Nielsen; A Gamst; D Morton; D Wingard
Journal:  J Nutr Health Aging       Date:  2008-01       Impact factor: 4.075

6.  Zinc and the aging brain.

Authors:  Johnathan R Nuttall; Patricia I Oteiza
Journal:  Genes Nutr       Date:  2013-12-24       Impact factor: 5.523

7.  Carbonic anhydrase I, II, and VI, blood plasma, erythrocyte and saliva zinc and copper increase after repetitive transcranial magnetic stimulation.

Authors:  Robert I Henkin; Samuel J Potolicchio; Lucien M Levy; Ramy Moharram; Irina Velicu; Brian M Martin
Journal:  Am J Med Sci       Date:  2010-03       Impact factor: 2.378

Review 8.  Copper in the brain and Alzheimer's disease.

Authors:  Ya Hui Hung; Ashley I Bush; Robert Alan Cherny
Journal:  J Biol Inorg Chem       Date:  2009-10-28       Impact factor: 3.358

9.  Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients.

Authors:  Rosanna Squitti; Carlo C Quattrocchi; Gloria Dal Forno; Piero Antuono; David R Wekstein; Concetta R Capo; Carlo Salustri; Paolo M Rossini
Journal:  Biomark Insights       Date:  2007-02-07

10.  ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain.

Authors:  Nancy Beyer; David Tr Coulson; Shirley Heggarty; Rivka Ravid; G Brent Irvine; Jan Hellemans; Janet A Johnston
Journal:  Mol Neurodegener       Date:  2009-12-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.